Sanofi bids $9.3B for Medivation

Apr. 28, 2016 2:59 AM ETSanofi (SNY)SNY, MDVNBy: Yigal Grayeff, SA News Editor7 Comments
  • French pharmaceuticals group Sanofi (NASDAQ:SNY) has offered to acquire U.S. biotech company Medivation (NASDAQ:MDVN) in an all-cash deal valued at $9.3B.
  • Sanofi has offered $52.50 a share, representing a 50% premium over Medivation's recent volume weighted average share price prior to takeover speculation.
  • Medivation's shares closed at $52.05 yesterday, giving it a market cap of $8.5B.
  • "Last November, Sanofi outlined our mid-term strategy, which includes rebuilding our position in oncology," says Sanofi CEO Olivier Brandicourt. "With Medivation's best-in-class offerings in prostate cancer, we believe a combination would benefit patients and...generate value for shareholders of both companies.
  • Previously
  • PR

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.